Dr. Alain Chaglassian serves as the Vice President of U.S. Medical at Blue Earth Diagnostics, where he has worked for more than eight years. He originally joined the organization as a Medical Science Liaison and has since become deeply committed to supporting patients with prostate cancer and advancing next‑generation imaging technologies.

He brings extensive oncology and research experience to his role and holds both a Medical Degree and a Master of Public Health. Based in the Boston area, Dr. Chaglassian leads key data‑generation initiatives at Blue Earth and represents the company at major national conferences, strengthening collaborations with clinicians, researchers, and other stakeholders across the field.

Presentation:

Dr. Chaglassian will lead a talk about the use of prostate-specific membrane antigen (PSMA) Positron-emission tomography (PET), which can help inform doctors about prostate cancer diagnosis

PSMA PET imaging is a special X-ray that allows physicians to see prostate cancer cells with
much better accuracy than many standard imaging studies, e.g., CT scan, MRI, and bone scans.
PSMA is a protein on the surface of prostate cells and is found in high amounts on many prostate
cancer cells. Simply, PSMA acts like a flag on prostate cancer cells that can be targeted and seen
when doctors use a special radioactive agent called a tracer.

During a PSMA PET scan, a small amount of a tracer is injected into the bloodstream. This
tracer attaches to PSMA proteins allowing the PET scanner to show areas where prostate cancer
cells may be located in the body. Because the tracer seeks out PSMA “flags,” the PET scan can
often detect very small areas of cancer that may not be visible on standard imaging studies. This
technology can identify small lymph node, bone, or soft tissue metastases that may influence
decisions regarding surgery, radiation therapy, systemic treatment, or targeted therapies such as
radioligand therapies.

PSMA PET has become increasingly important for initial staging of higher-risk prostate cancer,
detection of recurrence after treatment, and evaluation of metastatic disease. As experience with
PSMA PET grows, it is reshaping how clinicians assess the extent and biology of prostate cancer
in patients.

new Info